Agomelatine: Innovation for the Benefit of Depressed Patients FOREWORD

被引：0
|
作者：
Rouillon, Frederic [1 ]
机构：
[1] Univ Paris 05, Clin Malad Mentales & Encephale, St Anne Hosp, Paris, France
来源：
CNS DRUGS | 2009年 / 23卷
关键词：
D O I：
10.2165/11318610-000000000-00000
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [41] Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France
    Gorwood, Philip
    Benichou, Jacques
    Moore, Nicolas
    Wattez, Marine
    Secouard, Marie-Cecile
    Desobry, Xavier
    Picarel-Blanchot, Francoise
    de Bodinat, Christian
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (11) : 1009 - 1020
  • [42] Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France
    Philip Gorwood
    Jacques Benichou
    Nicolas Moore
    Marine Wattez
    Marie-Cécile Secouard
    Xavier Desobry
    Françoise Picarel-Blanchot
    Christian de Bodinat
    [J]. Clinical Drug Investigation, 2020, 40 : 1009 - 1020
  • [43] The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study
    Gorwood, Philip
    Benichou, Jacques
    Moore, Nicholas
    alvarez Martinez, Enric
    Mertens, Joost
    Aguglia, Eugenio
    Figueira, Maria-Luisa
    Falkai, Peter
    Olivier, Valerie
    Wattez, Marine
    Picarel-Blanchot, Francoise
    de Bodinat, Christian
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2021, 36 (01) : 1 - 11
  • [44] A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
    Robert H. Howland
    [J]. Drug Safety, 2011, 34 : 709 - 731
  • [45] A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
    Howland, Robert H.
    [J]. DRUG SAFETY, 2011, 34 (09) : 709 - 731
  • [46] REGULATION AND INNOVATION - FOREWORD
    WEBBER, WL
    [J]. LAW AND CONTEMPORARY PROBLEMS, 1979, 43 (01) : 1 - 3
  • [47] Innovation and Adaptation Foreword
    Martinez, S. F.
    [J]. PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2021, 32 (02) : 1 - 1
  • [48] CONTROLLED TRIALS: DO THEY TELL US WHAT WILL BENEFIT OUR DEPRESSED PATIENTS?
    Hawley, C. J.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 : A11 - A11
  • [49] EFFICACY OF AGOMELATINE IN MORE ANXIOUS ELDERLY DEPRESSED PATIENTS. A RANDOMIZED, DOUBLE-BLIND STUDY VS PLACEBO
    Heun, R.
    Corral, R. M.
    Ahokas, A.
    Nicolini, H.
    Teixeira, J. M.
    Dehelean, P.
    [J]. EUROPEAN PSYCHIATRY, 2013, 28
  • [50] Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
    Kang, Ruiying
    He, Yan
    Yan, Yuxiang
    Li, Zhiwu
    Wu, Yeqing
    Guo, Xiaojuan
    Liang, Zhigang
    Jiang, Jun
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1307 - 1311
12345